Enhanced usual care + Storytelling for Airflow Obstruction, Chronic

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Baystate Health, Springfield, MA
Airflow Obstruction, Chronic+3 More
Storytelling - Behavioral
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

Chronic Obstructive Pulmonary Disease (COPD) affects approximately 16 million Americans and is characterized by recurrent exacerbations that lead to 1.5 million Emergency Department visits and 700,000 hospitalizations annually. Pulmonary rehabilitation (PR) is a structured program of exercise and self-management support that has been proven to relieve shortness of breath and increase quality of life when initiated after an exacerbation, but unfortunately, few eligible patients participate. This project will compare the effectiveness of two novel strategies - one involving video narratives of other patients telling their story of how they overcame challenges and completed PR, the other involving telephonic peer coaching with an individual with lived experience - to enhanced usual care, and to each other, at increasing patient participation in PR after an exacerbation.

Eligible Conditions

  • Airflow Obstruction, Chronic
  • Chronic Obstructive Pulmonary Disease (COPD)

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Airflow Obstruction, Chronic

Study Objectives

1 Primary · 3 Secondary · Reporting Duration: 12 months

12 months
Change in GAD-7 from enrollment to 12 months - For Peer coach subjects
Change in MOS Social Support Survey from enrollment to 12 months - For Peer coach subjects
Change in SGRQ-C from enrollment to 12 months Change in PHQ-9 from enrollment to 12 months - For Peer coach subjects
Change in SWLS from enrollment to 12 months - For Peer coach subjects
Change in UCLA Loneliness Scale from enrollment to 12 months - For Peer coach subjects
Change in mMRC dyspnea scale from enrollment to 12 months - For Peer coach subjects
6 months
Any attendance (yes/no) at PR within 6 months of randomization.
Change in CRQ from randomization to 6 months
Change in GAD-7 from randomization to 6 months
Change in MOS Social Support Survey from randomization to 6 months
Change in PHQ-9 from randomization to 6 months
Change in UCLA Loneliness Scale from randomization to 6 months
Change in mMRC dyspnea scale from randomization to 6 months
Completion of ≥6 PR sessions within 6 months of randomization
Time to first PR session attended
Total # of COPD Exacerbations
Total # of ED visits
Total # of Hospitalizations
Total number of PR sessions completed within 6 months of randomization.

Trial Safety

Safety Progress

1 of 3

Other trials for Airflow Obstruction, Chronic

Trial Design

3 Treatment Groups

Enhanced usual care
1 of 3
Enhanced usual care + Storytelling
1 of 3
Enhanced usual care + Peer support
1 of 3
Active Control

305 Total Participants · 3 Treatment Groups

Primary Treatment: Enhanced usual care + Storytelling · No Placebo Group · N/A

Enhanced usual careNoIntervention Group · 1 Intervention: Enhanced usual care · Intervention Types:
Enhanced usual care + Storytelling
Behavioral
ActiveComparator Group · 1 Intervention: Storytelling · Intervention Types: Behavioral
Enhanced usual care + Peer support
Behavioral
ActiveComparator Group · 1 Intervention: Telephonic Peer Coaching · Intervention Types: Behavioral

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 12 months
Closest Location: Baystate Health · Springfield, MA
2014First Recorded Clinical Trial
0 TrialsResearching Airflow Obstruction, Chronic
9 CompletedClinical Trials

Eligibility Criteria

Age 18+ · All Participants · 6 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have received treatment for COPD exacerbation in either inpatient or outpatient setting.
You have been referred for pulmonary rehabilitation.
You are willing to participate in calls with peer coach and to view storytelling videos.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.